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• The challenges in measuring quality of life when health fluctuates for use in economic 
evaluation have received little attention, with only a few studies focusing on particular 
issues within specific studies/conditions.  
• This paper highlights the potential issues in measuring quality of life and calculating QALYs 
more broadly when health fluctuates and the influence on economic evaluation 
• There is potential in the current practice of economic evaluations of conditions with 
fluctuating health states to distort treatment decisions away from the optimal allocation 
 
Abstract  
Recurrent fluctuations in health states can occur due to long-term conditions with episodic symptoms 
or through side effects of cycles of treatment. Fluctuations and associated duration of symptoms can 
be predictable (e.g. side effects of chemotherapy treatment) or unpredictable (e.g. relapse in multiple 
sclerosis). Such recurrent fluctuations in health states can have an important impact on a person’s 
health-related quality of life. When symptoms vary by time of day, day of the week, or during the month, 
it is challenging to obtain reliable health-related quality of life estimates for use in assessing cost-
effectiveness of interventions.  
The adequacy of the quality of life estimate will be impacted by: (1) the standard recall period associated 
with the chosen measure (e.g. ‘health today’ for EQ-5D, ‘past month’ for SF-6D) and the way that 
respondents understand and make judgements about these recall periods, (2) the chosen timepoints 
for assessing health-related quality of life in relation to the fluctuations in health, and (3) the assumptions 
used to interpolate between measurement time points and thus calculate the QALYs.  
These issues have not received sufficient methodological attention and instead remain poorly 
accounted for in economic analyses. There is potential for these issues to considerably distort treatment 
decisions away from the optimal allocation. This paper brings together evidence from health economics, 
psychology and behavioural economics to explore these challenges in depth; presents the solutions 
that have been applied to date; and details a methodological research agenda for measuring QALYs in 




1.0 Introduction  
Many international institutes recommend that quality-adjusted life years (QALYs) are used as a 
composite measure of length and health-related quality of life in economic evaluations.1-6 To capture 
health-related quality of life, generic instruments such as SF-6D (derived from SF-12 or SF-36),7,8 EQ-
5D9 and the HUI10,11 are recommended by the Second Panel on Cost-effectiveness in Health and 
Medicine.12 EQ-5D and SF-6D are commonly formally recommended across several countries, such as 
UK, Canada, Australia, New Zealand and Ireland(1,2,5,6,13); the National Institute for Health and Care 
Excellence (NICE) in the UK recommends both SF-6D and EQ-5D, but prefers EQ-5D.1 Health-related 
quality of life is then multiplied by the length of time in the given health state to estimate the QALY 
summary measure of health outcome. 
Despite being recommended for use, these health-related quality of life measures may be problematic 
in economic evaluations for conditions or treatments that cause fluctuations in health-related quality of 
life. Fluctuations can occur in any person, but they are particularly prevalent in: (1) long-term conditions 
that have episodic symptoms; (2) responses to a trigger (e.g. stress increasing the likelihood of a 
seizure in epilepsy) or allergen, or (3) side effects of treatment. These fluctuations can be predictable 
(e.g. side effects of chemotherapy treatment) or unpredictable (e.g. relapse in multiple sclerosis). In 
some instances, minor or short-term changes in mental or physical health may be less likely to influence 
healthcare decision-making, but recurrent fluctuations that are regularly experienced can cause 
considerable variation in health and could affect decisions about treatment and care. The remainder of 
this paper is concerned with recurrent fluctuations.  
Due to their nature (Table 1), conditions or treatments with recurrent fluctuating states are difficult to 
measure. Standard measurement and analytic approaches applied to ‘typical’, relatively steady 
conditions, are not suitable when fluctuations are recurring. This is due to: (1) the recall periods, (2) the 
timing of assessment, (3) the analytical assumptions used to estimate the QALY, and (4) the valuation 
methods employed to generate the health-related quality of life values. The focus of this paper is on the 
first three of these, which are broadly concerned with measurement rather than valuation. Valuation 
methods will be discussed in a separate paper.  
These issues have received insufficient methodological attention and are poorly accounted for in 




trial economic evaluations are subject to these concerns. If inappropriate methods are used in either of 
these applications of research, health-related quality of life estimates could be poor and economic 
recommendations to decision-makers misleading. In addition to current approaches to healthcare, 
these problems are of even greater concern in personalised medicine, where a ‘one size fits all’ 
approach to treatment and care of patients is no longer considered to be appropriate and the adequate 
estimation of health-related quality of life is essential for treatment to be appropriately tailored towards 
individual’s needs.  
This paper brings together evidence from health economics, psychology and behavioural economics to 
explore these challenges in depth, it outlines the relevance to both trial-based and model-based 
economic evaluations, describes the solutions that have been applied to date, and presents a 
methodological research agenda for measuring and calculating QALYs in recurrent fluctuating health 
states. 
 
2.0 Measuring QALYs in recurrent fluctuating health states 
Typically, within trial economic evaluations are based exclusively on resource use and health-related 
quality of life data that are prospectively collected during a randomised controlled trial. Whilst model-
based economic evaluations can also be carried out alongside trials, data from other sources, such as 
observational studies, can be incorporated. For example, policy decisions made by NICE in the UK and 
other international institutes are generally based on the cost-effectiveness results of a decision model. 
The recommendations from the UK NICE guidelines manual, which provide a similar message to other 
international institutes, state that “A cost-effectiveness analysis could be modelled around a single well 
conducted randomised controlled trial, or by using decision-analytic techniques with probability, cost 
and health outcome data from a variety of published sources” (1The Guidelines Manual, 2012, pp 106). 
Any economic evaluation relies on good quality data collection that captures important changes in 
health. In both within trial economic evaluations and decision model-based economic evaluation, the 
timing of assessment of any outcome and the recall period used can introduce bias in the measurement 
of recurrent fluctuating health states by ignoring the temporal patterns of health-related quality of life in 





2.1 Timing of assessment 
Data in observational studies can be collected through longitudinal cohort studies, take a snapshot of 
the population at a certain point in time through cross-sectional surveys, or can be analysed 
retrospectively through case control studies. In clinical trials, data collection is either event driven (e.g. 
questionnaires completed during routine GP visits or following an event) or time driven (e.g. 
questionnaires completed periodically at set time periods).14 In any of these cases, for both predictable 
and unpredictable conditions, the resultant assessments of health-related quality of life may not 
comprehensively reflect patients’ experiences and could lead to an overestimation or underestimation 
of outcomes.15 This is because the patient may or may not be experiencing episodes of ill-health at the 
point of assessment or at each measurement time point; indeed, at the point of assessment the patient 
may be at the worst point of the fluctuation, best point of fluctuation, or at some point in-between (Figure 
1). When fluctuations are unpredictable and random and if the sample size is large enough, on average, 
the quality of life assessment could be argued to be unbiased. But, even in this case there will be great 
variation in scores, which results in imprecise estimates.  Finally, given symptoms are fluctuating, it is 
unclear what patients are taking into consideration when completing questionnaires, so it should not be 
assumed that a large sample size will overcome the matters described. 
Concerns with the current implementation of approaches to measure health-related quality of life have 
been raised in respect of several recurrent fluctuating health states.16 Particular attention has been paid 
to this issue in chemotherapy trials. Recent trials have collected EQ-5D at: baseline, 3 months, 6 
months, 12 months17 or 6 weeks, 16 weeks and 12 months18; or every 3 weeks19 when chemotherapy 
is administered. Several studies in cancer chemotherapy have shown that the timing of assessment of 
cancer-specific measures can significantly influence health-related quality of life results.15,20-24 The most 
severe effects of chemotherapy tend to occur during the first week of treatment, with partial or complete 
recovery by the day when chemotherapy is next administered.15 Measurement of health-related quality 
of life is commonly taken on the day of treatment for logistical reasons and hence underestimates 
symptom burden, as treatment side effects will be missed.15 The literature in non-recurrent acute events 
or illnesses (for example, hepatitis A and total knee arthroplasty) shows that the timing of assessment 
can significantly influence cost-effectiveness results when using EQ-5D or SF-6D.25,26 even when 





2.2 Recall periods 
When health is fluctuating, the health-related quality of life information gathered in questionnaires, such 
as EQ-5D and SF-12, can be influenced by the recall period used and can unduly influence the data 
that are used in either economic evaluation type. Problems with recall periods have been discussed in 
relation to healthcare usage,27,28 but much less attention has been paid to the recall periods of quality 
of life measures used in health economics. The recall periods of commonly used measures (see Table 
2) vary from the immediate (such as ‘health today’ or ‘current status’) to longer time periods (such as 
‘health over the past four weeks’). Some measures do allow a choice of recall periods (for example, 
HUI, SF-36), but overtime one recall period has been commonly used in studies and appear to have 
become the standard timeframe for each measure. The alternative timeframes seem to be less 
commonly used.29  
Assuming respondents adhere to the recall period, measures with shorter recall periods (such as EQ-
5D’s ‘health today’), could result in changes in health-related quality of life being missed if the patient is 
not experiencing symptoms in that short time period, or indeed, if the measure is completed earlier in 
the day rather than later. In questionnaires with longer recall periods (such as SF-36/SF-12’s ‘past 4 
weeks’), patients may focus on the worst health state, construct an average, or focus on recovery.30 If 
the respondent experiences a change in health state during the recall period it is not clear what is 
reported.30  
Longer recall periods have also been found to lead to a reduction of accuracy in recall due to memory 
problems as well as perceptions of events.31 With respect to pain, findings suggest that patients’ 
memories, and their response to questionnaires with retrospective recall periods, is determined by the 
worst and end part of an episode or day — known as the peak-end rule. 32,33 However, anticipatory 
emotions associated with knowing that a change in state is due to occur and the speed at which the 
change in state occurs are also thought to influence responses to retrospective questionnaires — both 
of which are relevant factors for recurrent fluctuating health states that are not currently taken into 
consideration.34 Other factors that are not considered when health is fluctuating, but can influence 
recalled responses, are mood or person’s state at the time of completion, the amount of time that has 




concepts could be affecting responses, but there is not currently a clear enough understanding of how 
patients complete questionnaires to know what the responses reflect.  
 
 
3.0 Calculating QALYs and influence on economic evaluations 
Together with the measurement concerns outlined, the analytical approach used to estimate the QALY, 
the assumptions used and the approaches to handle missing data when health fluctuates can impact 
cost-effectiveness results regardless of the economic evaluation type employed. There are also some 
additional aspects of model-based economic evaluations that are impacted when health fluctuates that 
are discussed.  
 
3.1 Assumptions of the QALY 
The assumptions used to interpolate between measurement time points and thus to calculate the QALY 
can be problematic in estimating values for recurrent fluctuating health states. Commonly, a linear 
relationship between measurement time points is assumed in calculating the area under the curve to 
obtain a QALY value.37 A linear relationship implies that changes in health-related quality of life show a 
constant rate of change between measurement time points (Figure 2). So, if the timing of assessment 
is inappropriate, the estimate of the QALY value is likely to be inaccurate when using linear interpolation. 
The changes in health-related quality of life may be over- or under-estimated in the QALY calculation. 
Although it has not been explored in recurrent fluctuating states, in the previous example of a one-off 
acute illness (hepatitis A) a difference in results was observed when three alternative analytical choices 
were explored to estimate the QALY for two different measure, SF-6D and EQ-5D.25 The analytic 
choices included patients having: (1) constant health-related quality of life for the duration of the illness, 
when only one health-related quality of life estimate is available, which is represented by the area of a 
rectangle; (2) linear improvement in health-related quality of life; or (3) marginal improvement every 
day, assuming an exponential change. The impact of the assumption on the results may be more 




discrepancies between estimated and experienced health-related quality of life, and emphasising the 
need to carefully consider the assumptions made to calculate the QALY and to justify the approach.   
 
3.2 Missing data 
Missing data occurs in most circumstances and health-related quality of life data are often imputed in 
economic evaluations. When health is fluctuating and health-related quality of life data are missing, 
assumptions of Missing At Random (MAR) or Missing Completely At Random (MCAR) are less likely to 
hold than for missing data in ‘steady’ conditions. Missing Not At Random (MNAR) may be more likely 
to occur as data may be missing at certain timepoints because the patient was experiencing bad days. 
Simple imputation methods, which can produce bias in any circumstance, such as last observation 
carried forward or next observation carried backward can be even more prone to bias if the number of 
missing observations is high or sequential in fluctuating states. More comprehensive methods to handle 
missing data, such as multiple imputation, are commonly used but can also introduce bias when health 
fluctuates. In multiple imputation, values are randomly and repeatedly drawn from an assigned 
distribution based on the existing observed data and the average used to impute the missing value.38 
Here, if patients are more commonly asked to respond at ‘good’ points during the cycle than at ‘bad’ 
points (as in chemotherapy trials) the imputation will largely be based on ‘good’ scores biasing the 
results. If fluctuations are predictable, information about the time point of the cycle should be 
incorporated into the regression model used to predict values for missing data to avoid biasing results. 
However, suitable approaches to multiple imputation for unpredictable fluctuations that can occur at 
any time have not yet been recommended.  
 
3.3 Decision-modelling and trial based economic evaluations 
In addition to the problems raised so far for model-based and within-trial economic evaluations, there 
are some additional aspects of model-based economic evaluations that need to be considered when 
health fluctuates.  
Such concerns specific to decision-model based economic evaluations, include whether suitable health-




model structure, and whether appropriate assumptions are used to assign health-related quality of life 
data to model health states. In addition, the health-related quality of life impact of the anticipatory 
feelings of the next exacerbation should also be appropriately considered by the analyst when assigning 
health-related quality of life values to mutually exclusive states (e.g. remission and relapse). Efforts are 
made by institutes and researchers, such as in the NICE guidelines manual and the guide to methods 
of technology appraisal1 and the Phillips checklist for decision models,39 to encourage researchers to 
justify structural assumptions and model inputs and to state methods used to appraise data sources 
and explore uncertainty, but these guides are understandably broad so they can be applied to many 
circumstances.  
Box 1 details the areas for concern in both within-trial and decision-model based economic evaluations 




Box 1. Checklist of issues to consider when conducting a within-trial or model-based 
economic evaluation when health fluctuates  
1. Does the condition or treatment cause fluctuating health? 
i. Are the changes predictable or unpredictable? 
 
2. Are the outcomes measured appropriately (observational study, trials, meta-analysis)? 
a. Timing of assessment/ when was quality of life collected 
i. Could the timing of assessment influence the results given the condition or treatment 
pathway? 
ii. Are the outcomes always assessed at the same time point? 
iii. Are fluctuations, exacerbations, good and bad days captured? 
iv. Could the timing of assessment influence the completion of the questionnaire? 
b. Recall measure/ how was quality of life collected 
i. Could changes in health occur within the recall period of the questionnaire? 
ii. Could the recall period cause fluctuations to be missed? 
iii. Could there be any reason, related to the fluctuations, that mean respondents are not 
completing the questionnaire as intended? 
 
3. Could the methods of analysis influence the results? 
a. Linear interpolation of the QALY 
i. Could important changes occur in health in between measurement time points?  
ii. Will linear interpolation ignore changes between measurement time points? 
b. Missing data 
i. Is MCAR or MAR a sensible assumption — could missingness be related to the 
respondent experiencing symptoms? 
ii. Are appropriate methods used to impute data that account for fluctuations? Is 
information on time point of missingness used to inform the imputation approach? 
 
4. Does the decision-model account for fluctuations? 
a. Model assumptions  
i. How are fluctuations accounted for in the model? 
ii. How are quality of life data applied to the model? Are appropriate assumptions used to 
fit data to health states? 
b. Model structure  
i. Does the model structure allow for changing health/exacerbations/ good and bad days? 
ii. Should the states be considered to be mutually exclusive? Are anticipatory emotions 







4.0 Solutions to date 
 
Some approaches have been used to overcome the challenges of measuring QALYs for particular 
conditions where health fluctuates and obtain more accurate values, but these have focused on the 
particular issues within the specific trials/studies, and have not attempted to develop more general 
solutions. Approaches used here include those based on recall (by changing the timeframe) and those 
based on timing of assessment (administering the questionnaire more frequently). 
 
4.1 Recall  
The availability of alternative recall periods for some of the standard measures, such as SF-36 and HUI, 
suggests that the need for different recall periods in certain settings has been identified. However, a 
search of the literature shows that the alternative recall periods of past week (SF-12 and HUI), or past 
2 weeks and 4 weeks for the HUI have not been widely used when health fluctuates.  
One approach that has, however, been used is to ask for responses by referring to different recall 
periods. In migraine, the temporary nature of a migraine and the changes that occur within an attack 
are difficult to capture, such that one study asked respondents to complete EQ-5D both with reference 
to their most recent attack and for their health outside of the attack in an attempt to obtain more accurate 
values.40 The authors suggested that these values can then be used in model-based economic 
c. Additional data source considerations 
i. Are the quality of life data suitable for the health state? 
ii. Are the quality of life data used across the states consistent? Due to the scores 
used, could the impact of fluctuations be inappropriately captured in multiple 
states? 
d. Cycle length 
i. Are changes expected within the time period of the cycle length? 





evaluations of migraine.40 Similarly, in Parkinson’s disease it is argued that the recall period of outcome 
measures (EQ-5D and a Parkinson’s specific measure) are unlikely to capture the variation in symptoms 
and functioning that occur within each day between treatment doses, as treatment effects begin to wear 
off.41 Consequently, patients were asked to complete EQ-5D-5L twice: according to their treatment ‘on-
time’, when treatment is effective and treatment ‘off-time’, when it is less effective.  Using the UK value 
set,42 the index scores between the two states differed by 0.23, which led the authors to conclude that 
the current use of EQ-5D cannot capture variation in symptoms and that both on and off-time must be 
captured in estimating health-related quality of life for Parkinson’s disease.  
In other instances, researchers have used problematic recall periods as one reason for developing a 
preference-based measure from an existing condition-specific  measure, as in the development of 
NEW-QoL-6D for epilepsy.43 Here, one justification for the new measure was that the recall period of 
‘health today’, used in EQ-5D, was seen as problematic. Though the appropriateness of this approach 
and the value of obtaining condition-specific QALYs is widely debated, condition-specific preference-
based measures have commonly been developed in conditions that fluctuate. The reasoning for 
developing these measures is unlikely to be exclusively due to concerns with recall periods of standard 
measures, but it is interesting to note that condition-specific measures use a variety of recall periods  
For example,  HAQ-DI for rheumatoid arthritis (past week), MSIS for multiple sclerosis (past 2 weeks), 
DLQI for psoriasis (past week), CFQ-R for cystic fibrosis (2 weeks), a combination of MSQ and HIT-6 
for migraine (48 hours and past 4 weeks), and CCQ for COPD (past week or 24 hours) all have different 
recall periods to those used in generic measures which is likely to have been changed to increase the 
likelihood of capturing fluctuations in the condition.  
Similarly, mapping algorithms have been developed from condition-specific measures to generic 
preference-based measure, such as EQ-5D, in many conditions that fluctuate.44 This approach can be 
used to obtain QALYs when a preference-based measure has not been administered. The validity of 
mapping from condition-specific measures to generic preference-based measures, however, has not 
been assessed specifically with respect to the timeframe when the recall periods of the mapped 






4.2 Timing of assessment  
Rather than altering the recall period, other studies in conditions with fluctuating symptoms have altered 
the time at which the assessment is made.  One early example of altering timing of assessment exists 
using a measure that is not used to generate QALYs. In relapsing-remitting multiple sclerosis, a 
neurological condition that affects the nervous system, people with the condition experience prolonged 
periods of remission and unpredictable relapses, or exacerbations of their condition. To ensure health-
related quality of life was assessed comprehensively amongst patients in remission, one study 
demonstrated the feasibility of daily diary completion of the Euroqol Visual Analogue Scale (EQ-VAS) 
and symptom information for 6 weeks.45  
 
4.3 Calculation of the QALY 
Optimal timings of data collection and interpolation assumptions have not been proposed for fluctuating 
health states. But, recommendations have been made in one study on total knee arthroplasty, where a 
surgical intervention caused non-recurrent short-term fluctuations in health-related quality of life. 
Health-related quality of life increased rapidly in the first 3 months until it stabilised at 6 months. The 
influence of both various interpolations of the QALY and the longer lengths of time between timing of 
assessment were explored. For interpolation, an assumption of linear interpolation between timepoints 
was compared with interpolation through an assumed immediate (vertical) improvement in health-
related quality of life at the previous measurement time point followed by a horizontal line to the next 
timepoint. The addition of data from more measurement timepoints was also explored and the extent 
of the errors in QALYs gained was compared across both interpolation methods. The authors 
recommend that additional specific time points of data collection for SF-12, along with linear 
interpolation, minimised the error in the QALY estimation by most closely reflecting a ‘true’ estimate 
which had more frequent measurement time points.26 Similar research is required in recurrent 
fluctuating conditions.  
 




This final section of the paper focuses on a research agenda in relation to these measurement issues. 
As indicated at the start of the paper, further work will consider valuation issues. Inevitably, as this 
paper focuses on measurement, it is linked to the situation where the area under the curve approach 
is used for QALY computation. Alternative methods of valuation may be needed for situations where 
these under the curve approaches are rejected46.  Nevertheless, the focus of the research agenda 
here remains the measurement issues. 
 
5.1. Timing of assessment 
The most accurate estimates of QALYs would be expected when interval measurements are taken at 
each point where there is a change in health-related quality of life and are used alongside information 
on the duration of each state to generate relevant health-related quality of life curves. In some 
conditions, these points may be predictable, but in others they cannot be anticipated in advance.  
Research that is needed to explore potential solutions includes: (1) asking patients if they are currently 
experiencing symptoms when completing the questionnaire, particularly if fluctuations are unpredictable 
— if the sample size is sufficient, this approach will provide some sense of the treatment effect on 
health-related quality of life with the possibility of exploring different ranges in a sensitivity analysis to 
see the impact on results; or (2) validating quality of life scores by identifying other studies that have 
specifically elicited quality of life during a fluctuation, if available, these values could be tested in a 
sensitivity analysis.  
Other areas for research related to both timing of assessment and approaches to questionnaire 
completion could lead to the development of ways of aligning patient and proxy responses, if patients 
are able to complete measures at some points in their illness and not at others. Additionally, as patients 
are fluctuating between health states instead of remaining in one health state, the extent of adaptation 
over periods of assessment could also be explored to determine if patients’ responses overtime are 






With respect to recall periods, research should include understanding how patients with recurrent 
fluctuating symptoms complete questionnaires with standard recall periods: what patients are taking 
into consideration depending on the timing of assessment and how much the recall period influences 
responses. The process and appropriateness of tailoring measure recall periods to each condition could 
also be tested, followed by research to identify the extent to which changes in recall affect results as 
well as ease of completion for patients. For example, it may be easier for patients to complete a 
questionnaire if they are asked to specifically refer back to a particular episode rather than using a 
standard recall.   
 
5.3. Calculation of the QALY 
Further, given the influence of timing of assessment and analytical assumptions to calculate the QALYs 
in acute events, there is also a need to identify and assess new approaches against a ‘best estimate’ 
for measurement and make recommendations on the optimal approaches for timing of assessment, 
recall and interpolation assumptions for the QALY for recurrent fluctuating health states.  
Research should also be carried out to determine the extent to which the approaches used to impute 
data for predictable and unpredictable recurrent fluctuations impacts on the results. The incorporation 
of secondary data on the nature and pattern of health-related quality of life fluctuations into imputation 
models could be explored to better predict health-related quality of life scores.  
Finally, with respect to model-based economic evaluations, the checklist of issues presented in Box 1 
should be consulted to ensure that suitable data are used in the model and section 4 of the checklist 
should be used to ensure the model structure and assumptions account for fluctuating health. Such 
research should lead to more robust recommendations on the measurement of outcomes in recurrent 
fluctuating health states by identifying the extent of the problem and developing a systematic approach 
to account for the impact of recurrent fluctuating health states in economic evaluation. As discussed at 
the outset of this paper, this research can also contribute to methods of capturing outcomes in economic 
evaluations of personalised medicine and could lead to treatment decisions that have been made based 
on robust outcome data. To fully explore the value of the proposed solutions the research should be 
carried out in different contexts to determine the extent to which this theoretical problem is taking place 
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